Predictive Oncology Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a POAI research report →
Price Chart
About the company
Predictive Oncology Inc. (POAI), an organization driven by expertise and data, is dedicated to pioneering individualized cancer treatments through the application of artificial intelligence, primarily within the United States. The company conducts its operations across four distinct divisions: Helomics, zPREDICTA, Soluble, and Skyline.
- CEO
- Raymond F. Vennare
- IPO
- 2010
- Employees
- 23
- HQ
- Pittsburgh, MN, US
Get TickerSpark's AI analysis on POAI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.57M
- P/E
- -0.15
- Fwd P/E
- 4.09
- PEG
- -0.01
- P/S
- 3.10
- P/B
- 2.64
- EV/EBITDA
- 0.35
- Div Yield
- 0.00%
- Gross Margin
- 51.80%
- Op Margin
- -100.13%
- Net Margin
- -783.32%
- ROE
- -390.59%
- ROIC
- -3.86%
Latest fiscal year · YoY change
- Revenue
- $125.28K-92.3%
- Gross Profit
- $52.66K-93.4%
- Op Income
- $-28,425,165
- Net Income
- $-233,095,203-1810.4%
- EPS
- $-13.37-496.9%
- OCF Growth
- +16.7%
- FCF Growth
- +16.8%
- 52W High
- $45.90
- 52W Low
- $1.21
- 50D MA
- $8.42
- 200D MA
- $13.27
- Beta
- 1.35
- RSI (14)
- 45
- Avg Volume
- 141.65K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Axe Compute posted its first profitable quarter after the legacy business exit, with revenue more than doubling and management pointing to a large contracted backlog and pipeline to drive the next phase of growth.· November 17, 2026
- Revenue rose to $7.2 million, up 125% from $3.2 million in Q2, and the company reported its first positive operating income and net income.
- Q3 operating income was $6.8 million and net income was $11.5 million, helped by a $10.5 million gain on digital assets and a $4.6 million unrealized gain tied to the Helomics sale.
- Cash and cash equivalents ended at $147.7 million, while total assets were $686.1 million, largely funded by $569.3 million of customer prepayments.
- Management said signed contract value over the past seven months reached $3 billion, with an additional $266 million signed since Q2 and a $14.1 billion qualified pipeline.
- The company said its Q3 revenue came entirely from Axe Access; no revenue was recognized yet from Axe Build, with deployments expected to ramp through Q4 2026 and early 2027.
Q3 2026 revenue was $7.2 million, up 125% from $3.2 million in Q2. Operating income was $6.8 million versus an operating loss of $16.4 million in Q2, and net income was $11.5 million versus a net loss of $17.2 million. Adjusted EBITDA was a loss of $2.3 million for the quarter, and the 9-month adjusted EBITDA loss was $8.4 million. Cash and cash equivalents were $147.7 million at September 30, and total assets were $686.1 million, up nearly 12x from $52.9 million at year-end. Management said $569.3 million of customer prepayments funded the balance sheet, and contract liabilities made up the majority of liabilities. Looking ahead, management said the signed book is expected to be fully deployed across Q4 2026 and into 2027, with some new contracts already contributing in Q3 and the rest expected to activate through Q4 and early Q1.
Christopher Miglino framed the quarter as a turning point: the company is now a pure-play GPU-as-a-Service business after selling Helomics, and he emphasized that the model is built on signed, multiyear take-or-pay contracts with customer prepayments before hardware is ordered. He highlighted the Georgia cluster ownership change as a major milestone, saying it should improve gross margin and free cash flow, and pointed to more than $3 billion of signed contracts in the past seven months as evidence of demand. His tone was upbeat and confident, with repeated emphasis that the business is “just getting started.”
Jeremy Yaukey-Witter said Q3 revenue was $7.2 million, entirely from Axe Access, with no Build revenue recognized yet. He also detailed the profitability bridge: operating income of $6.8 million included a $10.5 million gain on digital assets, while net income of $11.5 million included a $4.6 million unrealized gain on the Helomics-related securities and note; adjusted EBITDA was a loss of $2.3 million. On the balance sheet, he highlighted $147.7 million of cash, $686.1 million of total assets, and $569.3 million of customer prepayments, plus a $42.9 million face-value deferred purchase price liability carried at $36.6 million net of discount and due by September 30, 2027 or earlier upon refinancing.
Analysts focused on GPU rental pricing, the shift toward inference, customer visibility, the definition of “qualified” pipeline, and how much power the company will need. Management said tighter U.S. regulation could push more demand back into the U.S. and support higher per-hour GPU pricing, while Kyle Okamoto said the company’s strategy is to offer location and configuration choice because inference requires proximity. On customer transparency, Miglino said NDAs are common in the industry and noted the customers are large, investment-grade buyers; on pipeline qualification, Okamoto said an opportunity is qualified only when technical needs, decision makers, timing, and commercial terms are known. For power, Okamoto gave initial megawatt estimates for Georgia, Sweden, the larger U.S. cluster, and the U.S. expansion, and said other sites have double-digit megawatts available with room to expand.
The company showed rapid top-line growth, its first profitable quarter on both operating income and net income, and a cash-rich balance sheet supported by large customer prepayments. Management also described a sizable contracted backlog, a $14.1 billion qualified pipeline, and deployments across four AI factories that are expected to convert into revenue over the next two quarters.
Most of the current profit was helped by non-operating mark gains, and adjusted EBITDA was still negative at $2.3 million, so underlying operating profitability is not yet fully established. Revenue was still concentrated in Axe Access, while the large Build contracts had not yet contributed to Q3 revenue, making execution and deployment timing critical. Management also acknowledged that not every pipeline opportunity will close, and the business depends on securing power, sites, and customer acceptance across a tight data-center market.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.2%
- Shares Outstanding
- 726.08K
- Float Shares
- 720.10K
of shares held by institutions
15 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 17.91K | ▲ 17.91K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Blacher Joshua | other | 9,389 |
| Nov 28, 25 | Vennare Raymond F | other | 2,373 |
| Oct 7, 25 | Matthews Shawn | other | 0 |
| Oct 8, 25 | McLaughlin Thomas Louis | other | 0 |
| Sep 9, 25 | CHUNG-WELCH NANCY | other | 64,680 |
| Sep 9, 25 | HANDLEY DANIEL E | other | 64,680 |
| Sep 9, 25 | Hawryluk Matthew | other | 64,680 |
| Sep 9, 25 | Rao Veena | other | 64,680 |
| Sep 9, 25 | ST. CLAIR GREGORY SR | other | 64,680 |
| Sep 9, 25 | Nuzum Charles Lee Sr | other | 64,680 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our POAI coverage
Recent articles, reports, and earnings notes.
No research on POAI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate POAI report →Predictive Oncology Q2 Earnings Call Highlights
defenseworld.net · Aug 19
Predictive Oncology (NASDAQ:POAI) Stock Price Passes Below Two Hundred Day Moving Average – Here’s What Happened
defenseworld.net · Apr 21
Predictive Oncology Q4 Earnings Call Highlights
defenseworld.net · Apr 3
Predictive Oncology (NASDAQ:POAI) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened
defenseworld.net · Mar 19
Predictive Oncology (NASDAQ:POAI) versus Mitesco (OTCMKTS:MITI) Head-To-Head Comparison
defenseworld.net · Feb 10
Financial Analysis: Predictive Oncology (NASDAQ:POAI) and Healthcare Triangle (NASDAQ:HCTI)
defenseworld.net · Jan 30
Predictive Oncology (NASDAQ:POAI) Shares Cross Below 200-Day Moving Average – Here’s What Happened
defenseworld.net · Jan 10
Predictive Oncology Becomes Axe Compute, Expanding Into High-Performance AI Infrastructure
globenewswire.com · Dec 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.